Esperion (NASDAQ: ESPR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 9:30 a.m. ET, with a live webcast available on the company investor site. A replay will be posted about two hours after the call and archived for ~90 days.
Esperion is a commercial-stage cardiometabolic biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with approvals in more than 40 countries and an R&D pipeline targeting ACLY biology, Primary Sclerosing Cholangitis, and renal diseases.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ESPR
+4.18%
25 alerts
+4.18%Session close to close
+5.6%Peak Tracked
-5.8%Trough Tracked
$746.03MMarket Cap
1.0xRel. Volume
In the Mar 31 session, ESPR gained 4.18%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +5.6% during that session.
Argus tracked a trough of -5.8% from its starting point during tracking.
Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
This announcement highlights Esperion’s upcoming presentation at the 25th Annual Needham Virtual Hea...
Analysis
This announcement highlights Esperion’s upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, providing another platform to communicate its cardiometabolic and rare disease strategy. It follows recent guideline recognition for bempedoic acid, strong FY2025 revenue growth, and an acquisition to expand the cardiovascular franchise. Investors may focus on how management uses this forum to elaborate on commercial traction, integration of new assets, and progress across its ACLY-focused pipeline.
Key Figures
Conference edition:25th AnnualConference date:April 13, 2026Presentation time:9:30 a.m. ET+5 more
Announcement of timing and webcast details for Q4 and FY2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive fundamental and guideline news has produced mixed reactions, with some strong gains but also notable selloffs on earnings and acquisition updates.
Recent Company History
Over the last month, Esperion reported strong FY2025 revenue of $403.1M and Q4 revenue of $168.4M, announced an acquisition of Corstasis with up to $255M in potential payments, and gained multiple Class 1 guideline recommendations for bempedoic acid. Despite these developments, shares saw double-digit declines on the acquisition and earnings, but a 7.58% gain on guideline news. Against this backdrop, the Needham conference participation fits into an active period of clinical, commercial, and strategic updates.
"developing and delivering innovative cardiometabolic and rare/orphan disease therapies."
Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.
rare/orphan diseasemedical
"innovative cardiometabolic and rare/orphan disease therapies."
A rare or orphan disease is a serious medical condition that affects a very small portion of the population compared with common illnesses. These conditions often lack approved treatments because they are uncommon and costly to research. For investors, they matter because regulatory incentives, smaller clinical trial sizes, and high unmet need can make successful therapies commercially valuable — similar to serving a tiny market that will pay a premium for a solution.
acly biologymedical
"The Company leverages deep domain expertise in ACLY biology to develop"
ACLY biology concerns the role of the enzyme ATP citrate lyase (ACLY) in converting cell fuel into acetyl units used to build fats and modify proteins, essentially acting like a factory machine that turns raw energy into construction materials for cells. Investors care because ACLY is a common drug target for conditions such as metabolic disease, fatty liver and some cancers; changes in ACLY-related research or therapies can affect the value of companies developing treatments or diagnostics.
"maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk"
Low-density lipoprotein cholesterol (LDL-C) is the portion of blood cholesterol carried by particles that deliver cholesterol to arteries; think of LDL-C as delivery trucks that can leave sticky deposits in vessel walls. Investors care because high LDL-C levels drive demand for tests, medications, medical devices and preventive care, influence clinical trial outcomes and regulatory decisions, and help determine future healthcare spending and revenue for companies in the cardiovascular sector.
renal diseasesmedical
"including treatments for Primary Sclerosing Cholangitis and renal diseases."
Renal diseases are conditions that damage the kidneys’ ability to filter waste, balance fluids, and regulate blood pressure, ranging from mild impairment to kidney failure that may require dialysis or transplant. For investors, these diseases drive demand for diagnostics, medicines, medical devices, and long-term care—think of kidneys as a home’s plumbing: when they fail, products and treatments to repair or replace that system become commercially important and can affect company revenues and regulatory scrutiny.
ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
When will Esperion (ESPR) present at the Needham Virtual Healthcare Conference?
Esperion will present on April 13, 2026 at 9:30 a.m. ET. According to Esperion, the presentation will be webcast live on the company investor site and a replay will be available about two hours after the call.
How can investors access the Esperion (ESPR) webcast for the April 13, 2026 presentation?
Investors can access the live webcast on Esperion's investor and media website. According to Esperion, the company will post a replay roughly two hours after the call and archive it for approximately 90 days.
What topics will Esperion (ESPR) likely cover at the April 13, 2026 Needham conference?
Expect discussion of commercial performance and pipeline progress, including ACLY biology programs. According to Esperion, the company markets two oral non-statin LDL-C therapies and is advancing candidates for PSC and renal diseases.
Will a replay of Esperion's (ESPR) April 13, 2026 presentation be available after the live event?
Yes, a replay will be available about two hours after the call and archived for roughly 90 days. According to Esperion, the replay will be accessible via the investor and media section of its website.
Does Esperion (ESPR) have commercial products to discuss during the April 13, 2026 presentation?
Yes, Esperion currently markets two oral, once-daily non-statin LDL-C therapies. According to Esperion, these products support its U.S. commercial infrastructure and global approvals across more than 40 countries.
Who should investors contact for more information about Esperion's (ESPR) April 13, 2026 webcast?
Investors can contact Alina Venezia at investorrelations@esperion.com and media can contact Tiffany Aldrich at corporateteam@esperion.com. According to Esperion, phone contacts are provided on its investor page for follow-up.
